General
Preferred name
SELINEXOR
Synonyms
KPT-330 ()
CS-2185 ()
Selinexor (KPT-330) ()
ATG-010 ()
Xpovio ()
P&D ID
PD010381
CAS
1393477-72-9
Tags
covalent binder
drug
available
Approved by
EMA
FDA
First approval
2019
Drug Status
investigational
approved
Drug indication
Liposarcoma
Multiple myeloma
Neuroendocrine cancer
Acute myeloid leukaemia
Recurrent glioblastoma
Solid tumour/cancer
Diffuse large B-cell lymphoma
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Selinexor (KPT-330) is an inhibitor of the nuclear export protein XPO1 (a.k.a. exportin 1) that is being developed as an anti-neoplastic agent by Karyopharm Therapeutics. It is a first-in-class inhibitor that exploits a novel mechanism of action compared to existing chemotherapeutics . The chemical structure is claimed in patent WO2013019561A1 (as compound 70) . (GtoPdb)
Compound Sets
19
AdooQ Bioactive Compound Library
A12582
Axon Medchem Screening Library
2336
ChEMBL Approved Drugs
CHEMBL3545185
ChEMBL Drugs
CHEMBL3545185
CovBinderInPDB
CBR001257
Drug Repurposing Hub
DrugBank
DB11942
DrugBank Approved Drugs
DB11942
DrugCentral
5330
DrugCentral Approved Drugs
5330
DrugMAP
DMBD4K3
Guide to Pharmacology
10036
Mcule NIBR MoA Box Subset
MCULE-1006401802
MedChem Express Bioactive Compound Library
HY-17536
NCATS Inxight Approved Drugs
31TZ62FO8F
NIH Approved Oncology Drugs
Novartis Chemogenetic Library (NIBR MoA Box)
ReFrame library
Selleckchem Bioactive Compound Library
kpt-330
External IDs
23
Properties
(calculated by RDKit )
Molecular Weight
443.09
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
2
Rotatable Bonds
5
Ring Count
3
Aromatic Ring Count
3
cLogP
3.39
TPSA
97.62
Fraction CSP3
0.12
Chiral centers
0.0
Largest ring
6.0
QED
0.36
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Member status
member
MOA
Exportin 1 inhibitor
exportin antagonist
Indication
multiple myeloma
Target
XPO1
XPO1/CRM1 inhibitor
CRM1
Pathway
Membrane Transporter/Ion Channel
Source data